SANT-2
Inhibitor of Sonic hedgehog (Shh) signaling
From Wikipedia, the free encyclopedia
SANT-2 is a small-molecule antagonist of the sonic hedgehog (Shh) pathway,[1] a developmental signaling cascade implicated in tissue patterning, stem cell maintenance, and the progression of various cancers. By targeting the smoothened (SMO) receptor, SANT-2 disrupts aberrant Shh pathway activation, thereby inhibiting downstream transcriptional programs that drive uncontrolled cell proliferation and survival.[1] Due to its potency and specificity, SANT-2 has become a tool for studying Hedgehog-dependent oncogenesis and holds potential as a lead compound for the development of targeted anticancer therapeutics.
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H26ClN3O4 |
| Molar mass | 479.96 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
SANT-2 is a potent antagonist of the Smoothened (SMO) receptor, a key component of the Sonic hedgehog (Shh) signaling pathway, displaying a dissociation constant (KD) of 12 nM for SMO binding. Its pharmacological profile is characterized by strong allosteric binding—similar to the first-in-class SMO antagonist SANT-1, interfering with the receptor’s activity even in the presence of endogenous and synthetic agonists. SANT-2 efficiently displaces radiolabeled SAG-1.3 and cyclopamine bound to SMO, with inhibition constants (Kd) of 7.8 nM and 8.4 nM, respectively, highlighting its high affinity and specificity for this receptor.[1][2][3]
Synthesis
SANT-2 is synthesized by coupling 2-chloro-5-nitrobenzoic acid with o-phenylenediamine to form a benzimidazole intermediate. Béchamp reduction of the nitro group affords the corresponding aniline, which is then coupled with 3,4,5-triethoxybenzoic acid via amide formation to yield SANT-2.[1]
